Welcome to our dedicated page for Integrated Biopharma news (Ticker: INBP), a resource for investors and traders seeking the latest updates and insights on Integrated Biopharma stock.
Integrated BioPharma Inc (INBP) provides essential updates for stakeholders tracking this pharmaceutical manufacturer's operations in vitamins, supplements, and contract services. This page serves as the definitive source for verified company announcements, offering investors and industry professionals direct access to critical developments.
Our curated news collection delivers timely insights into quarterly earnings, manufacturing facility expansions, and regulatory compliance milestones. Users gain strategic visibility into INBP's nutraceutical innovations and distribution partnerships while monitoring key performance indicators in the competitive health supplements market.
All content undergoes rigorous verification to ensure accuracy with SEC filings and official statements. The archive includes product launch announcements, strategic partnership details, and operational updates from INBP's manufacturing and distribution segments. Bookmark this resource to efficiently track the company's progress in meeting pharmaceutical-grade production standards and expanding its contract manufacturing clientele.
Integrated BioPharma, Inc. (OTCQX:INBP) reported a net loss of $35,000 for Q3 2022, contrasting with a net income of $516,000 in the same quarter last year. Revenue fell to $12.3 million, a 3.1% decrease from $12.8 million year-over-year. Operating income dropped significantly to $30,000 from $585,000 the previous year. The company attributes revenue decline to customer overstocking during the pandemic, despite offsetting some losses with increased sales to other customers.
Integrated BioPharma, Inc. (INBP) announced its financial results for the quarter and fiscal year ending June 30, 2022. Revenue decreased to $13.3 million for the quarter and $56.2 million for the fiscal year, down 22.2% and 11.6% year-over-year, respectively. Net income also fell, landing at $1.5 million ($0.05 per share) for the quarter and $3.8 million ($0.13 per share) for the year. The decline was attributed to increased safety stock and consumer demand changes during the pandemic, despite consistent revenue from major customers, which comprised 90% of total revenue.
Integrated BioPharma, Inc. (OTCQX:INBP) announced the resignation of Mr. Carl DeSantis as a Class I Director, with Mr. Damon DeSantis taking his place. The Co-CEOs expressed gratitude for Carl's service and optimism about Damon's experience in the nutraceutical sector, which they believe will be valuable for the Board. Damon has a notable history in the industry, including leadership roles at Celsius Holding, Inc. and Rexall Sundown. The company focuses on manufacturing and distributing nutritional products and acknowledges potential risks linked to market developments and ongoing uncertainties.
Integrated BioPharma, Inc. (OTCQX:INBP) reported a decline in revenue for the quarter ending March 31, 2022, totaling $15.6 million, down 8.4% from $17.1 million in the same period of 2021. Similarly, revenue for the nine-month period decreased to $43.0 million, a 7.6% drop from $46.5 million in 2021. Operating income fell from $1.7 million to $1.0 million for the quarter, and $4.5 million to $2.3 million for the nine months. Net income also declined to $0.8 million ($0.03 per share) from $1.2 million ($0.04 per share).
Integrated BioPharma, Inc. (OTCQX:INBP) reported its financial results for the quarter ended December 31, 2021. Revenue increased to $14.6 million, up 2.1% from $14.3 million in the same quarter of 2020. However, revenue for the six-month period decreased to $27.3 million, down 7.1% from $29.4 million. Operating income declined to $1.3 million for the six-month period, compared to $2.8 million in 2020. Net income for the quarter was $1.0 million or $0.04 per share, showing a slight decrease from the $1.2 million reported in 2020.
Integrated BioPharma, Inc. (OTCQX:INBP) reported a revenue of $12.8 million for the quarter ended September 30, 2021, down 16% from $15.2 million in the same quarter of 2020. Operating income fell to $0.6 million from $1.5 million. Net income also decreased to $0.5 million or $0.02 per share, compared to $1.0 million or $0.04 per share last year. The drop in revenue was attributed to reduced demand post-COVID surge, although the company maintained a stable client base, with two major customers accounting for 91% of sales.
Integrated BioPharma (INBP) reported a strong performance for the quarter and fiscal year ending June 30, 2021. Revenues for Q4 reached $17.1 million, up 26.7% year-over-year, with net income of $4.5 million or $0.15 per share. For the fiscal year, total revenue was $63.6 million, a 20.5% increase, accompanied by net income of $8.0 million or $0.27 per share. Key customers in contract manufacturing accounted for 92% of revenues, demonstrating stable demand.
Integrated BioPharma (INBP) reported a 25.2% revenue increase for Q1 2021, totaling $17.1 million compared to Q1 2020. For the nine-month period, revenue reached $46.5 million, up 18.6% year-over-year. Operating income also rose from $1.0 million to $1.7 million for Q1, and net income increased from $0.9 million to $1.2 million during the same period. The company emphasized the consistency of revenue from its major customers, contributing 92% to total revenue.
Integrated BioPharma, Inc. (OTCQX: INBP) has launched an updated investors website aimed at enhancing shareholder engagement. Effective April 8, 2021, the site features current stock quotes, historical financial data, news, and events. Co-CEOs Riva Sheppard and Christina Kay emphasize that the reactivation of email subscription alerts will facilitate better communication with shareholders. The company focuses on manufacturing and distributing vitamins, nutritional supplements, and herbal products, ensuring transparency for investors.
Integrated BioPharma, Inc. (OTCQX:INBP) announced its financial results for Q2 2020, revealing revenue of $14.3 million, a slight increase from $14.2 million in Q2 2019. For the six-month period, revenue rose 14.8% to $29.4 million. The company reported net income of $1.2 million ($0.04 per share) for Q2 2020, up from $1.0 million ($0.03 per share) in 2019. Operating income remained stable at $1.2 million for both periods. The Co-CEOs highlighted consistency in revenue from their top two customers, making up 92% of total revenue.
